Long-term results of sclerotherapy for dilated gastrojejunostomy after gastric bypass.

Background: Endoscopic sclerotherapy with sodium morrhuate of a dilated gastrojejunostomy in gastric bypass patients has been shown to narrow the diameter of the anastomosis and provide weight loss or weight stability 3-6 months after the procedure. Longer term results for this procedure are needed.

Methods: From 1999 to 2006, sclerotherapy was performed on 147 gastric bypass patients with a dilated gastrojejunostomy.

Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies.

Background: Sampling error regarding disease grade and stage has been ascribed to needle liver biopsies in patients with chronic liver disease. Although several studies evaluating sampling error in liver biopsies exist, none have investigated this phenomenon in patients with non-alcoholic fatty liver disease (NAFLD). This study aims to determine the rate and extent of sampling error in liver biopsies obtained from patients undergoing Roux-en-Y gastric bypass (RYGBP) surgery for morbid obesity.

Prevalence of non-alcoholic steatohepatitis in morbidly obese subjects undergoing gastric bypass.

Background: Obesity is the most common cause of non-alcoholic steatohepatitis (NASH). This is a prospective study to determine the incidence and severity of NASH in patients undergoing Roux-en-Y gastric bypass (RYGBP) for morbid obesity. We also examined the relationship between NASH and potential risk factors.

Treatment of dilated gastrojejunostomy with sclerotherapy.

Background: Dilation of the gastrojejunostomy after gastric bypass may result in weight gain. Many surgical and medical treatments have met with poor results. A feasibility study of endoscopic sclerotherapy (ST) of the gastrojejunostomy was performed, based on the known risk of esophageal stricture in the treatment of esophageal varices.